Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase.

Giordano V, De Falco G, Chiari R, Quinto I, Pelicci PG, Bartholomew L, Delmastro P, Gadina M, Scala G.

J Immunol. 1997 May 1;158(9):4097-103.

PMID:
9126968
2.
4.
5.

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC.

J Immunol. 1997 Sep 1;159(5):2212-21.

PMID:
9278309
6.

Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor.

Wang Y, Robledo O, Kinzie E, Blanchard F, Richards C, Miyajima A, Baumann H.

J Biol Chem. 2000 Aug 18;275(33):25273-85.

7.

Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.

Majka M, Ratajczak J, Villaire G, Kubiczek K, Marquez LA, Janowska-Wieczorek A, Ratajczak MZ.

Exp Hematol. 2002 Jul;30(7):751-60.

PMID:
12135673
10.
12.

Insulin receptor substrate-1 enhances growth hormone-induced proliferation.

Liang L, Zhou T, Jiang J, Pierce JH, Gustafson TA, Frank SJ.

Endocrinology. 1999 May;140(5):1972-83.

PMID:
10218944
14.

Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2.

VanderKuur J, Allevato G, Billestrup N, Norstedt G, Carter-Su C.

J Biol Chem. 1995 Mar 31;270(13):7587-93.

15.

Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes.

Kunisada K, Hirota H, Fujio Y, Matsui H, Tani Y, Yamauchi-Takihara K, Kishimoto T.

Circulation. 1996 Nov 15;94(10):2626-32. Erratum in: Circulation 1997 Apr 1;95(7):1975.

16.

Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.

Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H.

Circulation. 2003 Feb 18;107(6):798-802.

17.

New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway.

Gu H, Maeda H, Moon JJ, Lord JD, Yoakim M, Nelson BH, Neel BG.

Mol Cell Biol. 2000 Oct;20(19):7109-20.

18.

Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation.

Anhuf D, Weissenbach M, Schmitz J, Sobota R, Hermanns HM, Radtke S, Linnemann S, Behrmann I, Heinrich PC, Schaper F.

J Immunol. 2000 Sep 1;165(5):2535-43.

19.

Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.

Hermanns HM, Radtke S, Haan C, Schmitz-Van de Leur H, Tavernier J, Heinrich PC, Behrmann I.

J Immunol. 1999 Dec 15;163(12):6651-8.

20.

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L.

Biochem J. 1998 Sep 1;334 ( Pt 2):297-314. Review.

Supplemental Content

Support Center